Comparative Pharmacology
Head-to-head clinical analysis: MANNITOL 15 versus OSMITROL 15 IN WATER IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MANNITOL 15 versus OSMITROL 15 IN WATER IN PLASTIC CONTAINER.
MANNITOL 15% vs OSMITROL 15% IN WATER IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Increases plasma osmolality, drawing water from intracellular and interstitial spaces into the vascular compartment, thereby reducing intracranial pressure and intraocular pressure. Acts as an osmotic diuretic in the kidneys, increasing urine flow by inhibiting water reabsorption in the proximal tubule and loop of Henle.
Osmotically active agent that increases plasma osmolality, drawing water from intracellular and interstitial spaces into the vascular compartment, thereby reducing cerebral edema and intraocular pressure.
1-2 g/kg as a 15% solution intravenously over 30-60 minutes. Typical adult dose: 100-200 g (667-1333 mL of 15% solution) administered as a single dose for reduction of intracranial pressure or promotion of diuresis.
1.5-2 g/kg intravenous infusion over 30-60 minutes every 6-8 hours as needed for reduction of intracranial pressure or cerebral edema.
None Documented
None Documented
Terminal elimination half-life approximately 0.25-1.5 hours in normal renal function; prolonged to 24-36 hours in renal impairment.
Terminal half-life: 0.25–1.5 hours (15–90 minutes) in normal renal function; prolonged to 24–36 hours in anuria or severe renal impairment.
Primarily renal (90-100% as unchanged drug); negligible biliary/fecal elimination.
Renal: >90% unchanged by glomerular filtration; minimal tubular reabsorption or secretion. <10% metabolized in liver (negligible).
Category A/B
Category C
Osmotic Diuretic
Osmotic Diuretic